null Marina Klein, MD, M.Sc., FRCPC

Senior Scientist, RI-MUHC, 5252 de Maisonneuve site

Infectious Diseases and Immunity in Global Health Program

Centre for Outcomes Research and Evaluation

Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Infectious Diseases, MUHC



HIV • Hepatitis C • clinical trials • epidemiology • antiretrovirals • prospective cohort

Research Focus

My research program builds on years of multidisciplinary work leading one of the largest cohorts focused on HIV and hepatitis C virus (HCV) co-infection in the world. As Canada Research Chair in Clinical and Epidemiologic Studies of Chronic Viral Infections in Vulnerable Populations, I am documenting the impact of new HCV therapies on health outcomes, designing and testing tailored approaches to increase access to diagnosis and treatment, building capacity for research with Indigenous communities, and using evidence generated to advocate for policy change. My goal is to pave the way to eliminating HCV and other chronic viral infections in Canada and globally. To this end, I am leading an ambitious project called Montreal Sans Hep C, which aims to make Montreal the first City in North America to eliminate HCV.

Selected Publications

Click on Pubmed to see my current publications list

  • Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study.Int J Epidemiol 2010; 39(5):1162-9

  • Brunet L, Moodie EEM, Rollet K, Cooper C, Walmsley S, Potter M, Klein MB, and the Canadian Co-infection Cohort Investigators. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C co-infection: a longitudinal cohort analysis. Clin Infect Dis 2013; 57(5):663-670.

  • Saeed S, Strumpf E, Walmsley W, Rollet-Kurhajec K, Pick N, Martel Laferriere V, Hull M, Gill MJ, Cox J, Cooper C, Klein MB. How generalizable are the results from trials of Direct Antiviral Agents to people co-infected with HIV/Hepatitis C virus in the real world? Clin Infect Dis. 2016 Apr 1;62(7):919-26.

  • Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB; Canadian Co-infection Cohort Investigators. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clin Infect Dis . 2017 May 1;64(9):1154-1162.

  • Kronfli N, Young J, Wang S, Cox J, Walmsley S, Hull M, Cooper C, Martel-Laferriere V, Wong A, Pick N and Klein MB, for the Canadian Co-infection Cohort Study Investigators. Liver fibrosis in HIV-Hepatitis C virus (HCV) co-infection before and after sustained virologic response: what is the best non-invasive marker for monitoring regression? Clin Infect Dis. 2020 Jun 5;ciaa702.